Broadly neutralizing antibodies for therapy of viral infections

References

• Burton DR, Desrosiers RC, Doms RW, et al. HIV vaccine design and the neutralizing antibody problem. Nat Immunol. 2004;5(3):233–236.
   PubMed Web of Science ®Google Scholar
• Parren PW, Burton DR. The antiviral activity of antibodies in vitro and in vivo. Adv Immunol. 2001;77:195–262.
   PubMed Web of Science ®Google Scholar
• Klasse PJ, Sattentau QJ. Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J Gen Virol. 2002;83(Pt 9):2091–2108.
   PubMedGoogle Scholar
• Rizzuto CD, Sodroski JG. Contribution of virion ICAM-1 to human immunodeficiency virus infectivity and sensitivity to neutralization. J Virol. 1997;71(6):4847–4851.
   Web of Science ®Google Scholar
• Arthur LO, Bess JW Jr, Sowder RC 2nd, et al. Cellular proteins bound to immunodeficiency viruses: implications for pathogenesis and vaccines. Science. 1992;258(5090):1935–1938.
   Web of Science ®Google Scholar
• Pinna D, Corti D, Jarrossay D, Sallusto F, Lanzavecchia A. Clonal dissection of the human memory B-cell repertoire following infection and vaccination. Eur J Immunol. 2009;39(5):1260–1270.
   PubMed Web of Science ®Google Scholar
• Corti D, Lanzavecchia A. Broadly neutralizing antiviral antibodies. Annu Rev Immunol. 2013;31:705–742.
   PubMed Web of Science ®Google Scholar
• Gong RCW, Dimitrov DS. Candidate antibody-based therapeutics against HIV-1. BioDrugs. 2012;26(3):143–162.
   Web of Science ®Google Scholar
• Seaman MS, Janes H, Hawkins N, Grandpre LE, Devoy C. Tiered categorization of a diverse panel of HIV-1 Env pseudoviruses for assessment of neutralizing antibodies. J Virol. 2010;84(3):1439–1452.
   PubMed Web of Science ®Google Scholar
• Kunert R, Rüker F, Katinger H. Molecular characterization of five neutralizing anti-HIV type 1antibodies: identification of nonconventional D segments in the human monoclonal antibodies 2G12 and 2F5. AIDS Res Hum Retroviruses. 1998;14(13):1115–1128.
   PubMed Web of Science ®Google Scholar
• Zwick MB, Jensen R, Church S, et al. Anti-human immunodeficiency virus type 1 (HIV-1) antibodies 2F5 and 4E10 require surprisingly few crucial residues in the membrane-proximal external region of glycoprotein gp41 to neutralize HIV-1. J Virol. 2005;79(2):1252–1261.
   Web of Science ®Google Scholar
• Binley JM, Wrin T, Korber B, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol. 2004;78(23):13232–13252.
   PubMed Web of Science ®Google Scholar
• Walker LM, Phogat SK, Chan-Hui PY, et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326(5950):285–289.
   PubMed Web of Science ®Google Scholar
• Pancera M, Zhou T, Druz A, et al. Structure and immune recognition of trimeric pre-fusion HIV-1 Env. Nature. 2014;514(7523):455–461.
   PubMed Web of Science ®Google Scholar
• Walker LM, Huber M, Doores KJ, et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature. 2011;477(7365):466–470.
   PubMed Web of Science ®Google Scholar
• Pejchal R, Doores KJ, Walker LM, et al. A potent and broad neutralizing antibody recognizes and penetrates the HIV glycan shield. Science. 2011;334(6059):1097–1103.
   PubMed Web of Science ®Google Scholar
• Mouquet H, Scharf L, Euler Z, et al. Complex-type N-glycan recognition by potent broadly neutralizing HIV antibodies. Proc Natl Acad Sci U S A. 2012;109(47):E3268–E3277.
   PubMed Web of Science ®Google Scholar
• Bonsignori M, Hwang KK, Chen X, et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J Virol. 2011;85(19):9998–10009.
   PubMed Web of Science ®Google Scholar
• Huang J, Ofek G, Laub L, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491(7424):406–412.
   PubMed Web of Science ®Google Scholar
• Corti D, Langedijk JP, Hinz A, et al. Analysis of memory B cell responses and isolation of novel monoclonal antibodies with neutralizing breadth from HIV-1-infected individuals. PLoS One. 2010;5(1):e8805.
   PubMed Web of Science ®Google Scholar
• Li Y, Migueles SA, Welcher B, et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat Med. 2007;13(9):1032–1034.
   Web of Science ®Google Scholar
• Scheid JF, Mouquet H, Ueberheide B, et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science. 2011;333(6049):1633–1637.
   PubMed Web of Science ®Google Scholar
• Falkowska E, Ramos A, Feng Y, et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J Virol. 2012;86(8):4394–4403.
   Web of Science ®Google Scholar
• Klein F, Halper-Stromberg A, Horwitz JA, et al. HIV therapy by a combination of broadly neutralizing antibodies in humanized mice. Nature. 2012;492(7427):118–122.
   PubMed Web of Science ®Google Scholar
• Caskey M, Florian K, Lorenzi JC, et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature. 2015;522(7557):487–491. doi: 10.1038/nature14411.
   PubMed Web of Science ®Google Scholar
• Roehrig JT, Bolin RA, Kelly RG. Monoclonal antibody mapping of the envelope glycoprotein of the dengue 2 virus, Jamaica. Virology. 1998;246(2):317–328.
   PubMed Web of Science ®Google Scholar
• Cedillo-Barron L, Garcia-Cordero J, Bustos-Arriaga J, Leon-Juarez M, Gutierrez-Castaneda B. Antibody response to dengue virus. Microbes Infect. 2014;16(9):711–720.
   Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. A ligand-binding pocket in the dengue virus envelope glycoprotein. Proc Natl Acad Sci U S A. 2003;100(12):6986–6991.
   PubMed Web of Science ®Google Scholar
• Modis Y, Ogata S, Clements D, Harrison SC. Variable surface epitopes in the crystal structure of dengue virus type 3 envelope glycoprotein. J Virol. 2005;79(2):1223–1231.
   PubMed Web of Science ®Google Scholar
• Falconar AK. Identification of an epitope on the dengue virus membrane (M) protein defined by cross-protective monoclonal antibodies: design of an improved epitope sequence based on common determinants present in both envelope (E and M) proteins. Arch Virol. 1999;144(12):2313–2330.
   PubMed Web of Science ®Google Scholar
• Schieffelin JS, Costin JM, Nicholson CO, et al. Neutralizing and non-neutralizing monoclonal antibodies against dengue virus E protein derived from a naturally infected patient. Virol J. 2010;7:28.
   PubMed Web of Science ®Google Scholar
• Dejnirattisai W, Wongwiwat W, Supasa S, et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat Immunol. 2015;16(2):170–177.
   PubMed Web of Science ®Google Scholar
• Rouvinski A, Guardado-Calvo P, Barba-Spaeth G, et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature. 2015;520(7545):109–113.
   PubMed Web of Science ®Google Scholar
• Fibriansah G, Tan JL, Smith SA, et al. A highly potent human antibody neutralizes dengue virus serotype 3 by binding across three surface proteins. Nat Commun. 2015;6:6341.
   PubMed Web of Science ®Google Scholar
• Robinson LN, Tharakaraman K, Rowley KJ, et al. Structure-guided design of an anti-dengue antibody directed to a non-immunodominant epitope. Cell. 2015;162(3):493–504.
   PubMed Web of Science ®Google Scholar
• Kwo PY, Lawitz EJ, McCone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet. 2010;376(9742):705–716.
   PubMed Web of Science ®Google Scholar
• Gault E, Soussan P, Morice Y, et al. Evaluation of a new serotyping assay for detection of anti-hepatitis C virus type-specific antibodies in serum samples. J Clin Microbiol. 2003;41(5):2084–2087.
   Web of Science ®Google Scholar
• Meunier JC, Russell RS, Goossens V, et al. Isolation and characterization of broadly neutralizing human monoclonal antibodies to the e1 glycoprotein of hepatitis C virus. J Virol. 2008;82(2):966–973.
   PubMed Web of Science ®Google Scholar
• Lam BP, Jeffers T, Younoszai Z, Fazel Y, Younossi ZM. The changing landscape of hepatitis C virus therapy: focus on interferon-free treatment. Therap Adv Gastroenterol. 2015;8(5):298–312.
   PubMed Web of Science ®Google Scholar
• Cox AL. MEDICINE. Global control of hepatitis C virus. Science. 2015;349(6250):790–791.
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Ralston R, et al. Vaccination of chimpanzees against infection by the hepatitis C virus. Proc Natl Acad Sci U S A. 1994;91(4):1294–1298.
   PubMed Web of Science ®Google Scholar
• Raghuraman S, Park H, Osburn WO, Winkelstein E, Edlin BR, Rehermann B. Spontaneous clearance of chronic hepatitis C virus infection is associated with appearance of neutralizing antibodies and reversal of T-cell exhaustion. J Infect Dis. 2012;205(5):763–771.
   PubMed Web of Science ®Google Scholar
• Ball JK, Tarr AW, McKeating JA. The past, present and future of neutralizing antibodies for hepatitis C virus. Antiviral Res. 2014;105:100–111.
   PubMed Web of Science ®Google Scholar
• Sautto GA, Diotti RA, Clementi M. New therapeutic options for HCV infection in the monoclonal antibody era. New Microbiol. 2012;35(4):387–397.
   PubMed Web of Science ®Google Scholar
• Kong L, Giang E, Nieusma T, et al. Hepatitis C virus E2 envelope glycoprotein core structure. Science. 2013;342(6162):1090–1094.
   PubMed Web of Science ®Google Scholar
• Kong L, Giang E, Robbins JB, et al. Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1. Proc Natl Acad Sci U S A. 2012;109(24):9499–9504.
   PubMed Web of Science ®Google Scholar
• de Jong YP, Dorner M, Mommersteeg MC, et al. Broadly neutralizing antibodies abrogate established hepatitis C virus infection. Sci Transl Med. 2014;6(254):254ra129.
   PubMed Web of Science ®Google Scholar
• Keck ZY, Angus AG, Wang W, et al. Non-random escape pathways from a broadly neutralizing human monoclonal antibody map to a highly conserved region on the hepatitis C virus E2 glycoprotein encompassing amino acids 412–423. PLoS Pathog. 2014;10(8):e1004297.
   PubMed Web of Science ®Google Scholar
• Li Y, Pierce BG, Wang Q, et al. Structural basis for penetration of the glycan shield of hepatitis C virus e2 glycoprotein by a broadly neutralizing human antibody. J Biol Chem. 2015;290(16):10117–10125.
   Web of Science ®Google Scholar
• Sanchez AK, Zaki AS, Nabel SR, Ksiazek GJ, Peters TG, Filoviridae CJ. Marburg and Ebola viruses. In: Knipe DM, Howley PM, editors. Fields Virology. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2001:1279–1304.
   Google Scholar
• Towner JSS, Khristova TK, Albarino ML, et al. Newly discovered Ebola virus associated with hemorrhagic fever outbreak in Uganda. PLoS Pathog. 2008;4:e1000212.
   PubMed Web of Science ®Google Scholar
• Ksiazek TG, Rollin PE, Williams AJ, et al. Clinical virology of Ebola hemorrhagic fever (EHF): virus, virus antigen, and IgG and IgM antibody findings among EHF patients in Kikwit, Democratic Republic of the Congo, 1995. J Infect Dis. 1999;179(Suppl 1):S177–S187.
   PubMed Web of Science ®Google Scholar
• Dye JMH, Kuehne AS, Barth AI, et al. Postexposure antibody prophylaxis protects nonhuman primates from filovirus disease. Proc Natl Acad Sci U S A. 2012;109(13):5034–5039.
   PubMed Web of Science ®Google Scholar
• Maruyama T, Rodriguez L, Jahrling PB, et al. Ebola virus can be effectively neutralized by antibody produced in natural human infection. J Virol. 1999;73:6024–6030.
   PubMed Web of Science ®Google Scholar
• Parren PW, Geisbert TW, Maruyama T, Jahrling PB, Burton DR. Pre- and post-exposure prophylaxis of Ebola virus infection in an animal model by passive transfer of a neutralizing human antibody. J Virol. 2002;76:6408–6412.
   PubMed Web of Science ®Google Scholar
• Lee JE, Fusco ML, Hessell AJ, Oswald WB, Burton DR, Saphire EO. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature. 2008;454(7201):177–182.
   PubMed Web of Science ®Google Scholar
• Takada A, Ebihara H, Jones S, Feldmann H, Kawaoka Y. Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine. 2007;25:993–999.
   PubMed Web of Science ®Google Scholar
• Takada A, Feldmann H, Stroeher U, et al. Identification of protective epitopes on Ebola virus glycoprotein at the single amino acid level by using recombinant vesicular stomatitis viruses. J Virol. 2003;77:1069–1074.
   PubMed Web of Science ®Google Scholar
• Wilson JA, Hevey M, Bakken R, et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science. 2000;287:1664–1666.
   PubMed Web of Science ®Google Scholar
• Henao-Restrepo AM, Longini IM, Egger M, et al. Efficacy and effectiveness of an rVSV-vectored vaccine expressing Ebola surface glycoprotein: interim results from the Guinea ring vaccination cluster-randomised trial. Lancet. 2015;386(9996):857–866.
   PubMed Web of Science ®Google Scholar
• Marzi A, Robertson SJ, Haddock E, et al. Ebola vaccine. VSV-EBOV rapidly protects macaques against infection with the 2014/15 Ebola virus outbreak strain. Science. 2015;349(6249):739–742.
   PubMed Web of Science ®Google Scholar
• Pettitt J, Zeitlin L, Kim do H, et al. Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail. Sci Transl Med. 2013;5(199):199ra(13).
   Web of Science ®Google Scholar
• Qiu X, Wong G, Audet J, et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature. 2014;514:47–53.
   PubMed Web of Science ®Google Scholar
• Audet J, Wong G, Wang H, et al. Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep. 2014;4:6881.
   PubMed Web of Science ®Google Scholar
• WHO. Influenza (Seasonal). Available from: http://www.who.int/mediacentre/factsheets/fs211/en/. Accessed October 31, 2015.
   Google Scholar
• Laursen NS, Wilson IA. Broadly neutralizing antibodies against influenza viruses. Antiviral Res. 2013;98(3):476–483.
   PubMed Web of Science ®Google Scholar
• Osterhaus AD, Rimmelzwaan GF, Martina BE, Bestebroer TM, Fouchier RA. Influenza B virus in seals. Science. 2000;288(5468):1051–1053.
   PubMed Web of Science ®Google Scholar
• Lambert LC, Fauci AS. Influenza vaccines for the future. N Engl J Med. 2010;363(21):2036–2044.
   PubMed Web of Science ®Google Scholar
• Corti D, Voss J, Gamblin SJ, et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science. 2011;333(6044):850–856.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Bhabha G, Elsliger MA, et al. Antibody recognition of a highly conserved influenza virus epitope. Science. 2009;324(5924):246–251.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Friesen RH, Bhabha G, et al. A highly conserved neutralizing epitope on group 2 influenza A viruses. Science. 2011;333(6044):843–850.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Kashyap AK, Steel J, et al. Cross-neutralization of influenza A viruses mediated by a single antibody loop. Nature. 2012;489(7417):526–532.
   PubMed Web of Science ®Google Scholar
• Ekiert DC, Wilson IA. Broadly neutralizing antibodies against influenza virus and prospects for universal therapies. Curr Opin Virol. 2012;2(2):134–141.
   PubMed Web of Science ®Google Scholar
• Tan GS, Krammer F, Eggink D, Kongchanagul A, Moran TM, Palese P. A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo. J Virol. 2012;86(11):6179–6188.
   PubMed Web of Science ®Google Scholar
• Tan GS, Lee PS, Hoffman RM, et al. Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin. J Virol. 2014;88(23):13580–13592.
   PubMed Web of Science ®Google Scholar
• Pappas L, Foglierini M, Piccoli L, et al. Rapid development of broadly influenza neutralizing antibodies through redundant mutations. Nature. 2014;516(7531):418–422.
   PubMed Web of Science ®Google Scholar
• Benjamin E, Wang W, McAuliffe JM, et al. A broadly neutralizing human monoclonal antibody directed against a novel conserved epitope on the influenza virus H3 hemagglutinin globular head. J Virol. 2014;88(12):6743–6750.
   Web of Science ®Google Scholar
• Skountzou I, Satyabhama L, Stavropoulou A, et al. Influenza virus-specific neutralizing IgM antibodies persist for a lifetime. Clin Vaccine Immunol. 2014;21(11):1481–1489.
   Google Scholar
• Casadevall A, Pirofski L. The Ebola epidemic crystallizes the potential of passive antibody therapy for infectious diseases. PLoS Pathog. 2015;11(4):e1004717.
   PubMed Web of Science ®Google Scholar
• Casadevall A, Scharff M. Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis. 1995;21(1):150–161.
   PubMed Web of Science ®Google Scholar
• Hosty TS, Kissling RS, Schaeffer M, Wallace GA, Dibble EH. Human antirabies gamma globulin. Bull World Health Organ. 1959;20:1111–1119.
   PubMedGoogle Scholar
• Margaret A, Keller ERS. Passive immunity in prevention and treatment of infectious diseases. Clin Microbiol Rev. 2000;13(4):602–614.
   Web of Science ®Google Scholar
• Lee DC, Lederman HM. Anti-tetanus toxoid antibodies in intravenous gamma globulin: an alternative to tetanus immune globulin. J Infect Dis. 1992;166:642–645.
   Web of Science ®Google Scholar
• McCune TR, Johnson HK, MacDonell RC Jr, et al. The effect of polyimmune gammaglobulin for prophylaxis against reactivation cytomegalovirus infection in kidney and kidney/pancreas transplant recipients. J Am Soc Nephrol. 1992;2(10):1469–1474.
   Web of Science ®Google Scholar
• Almansa R, Eiros JM, Fedson D, Bermejo-Martin JF. Hyperimmune serum from healthy vaccinated individuals for Ebola virus disease? Lancet. 2014;2(12):e686.
   Web of Science ®Google Scholar
• Rybicki EP. Plant-based vaccines against viruses. Virol J. 2014; 11(1):205.
   PubMedGoogle Scholar
• Robbins JB, Schneerson R, Szu SC. Perspective: hypothesis: serum IgG antibody is sufficient to confer protection against infectious diseases by inactivating the inoculum. J Infect Dis. 1995;171(6):1387–1398.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Lewis MG, Stiegler G, et al. Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol. 1999;73(5):4009–4018.
   PubMed Web of Science ®Google Scholar
• Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med. 2000;6(2):207–210.
   PubMed Web of Science ®Google Scholar
• Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol. 1994;68(8):4821–4828.
   PubMed Web of Science ®Google Scholar
• Chen L, Kwon YD, Zhou T, et al. Structural basis of immune evasion at the site of CD4 attachment on HIV-1 gp120. Science. 2009;326(5956):1123–1127.
   PubMed Web of Science ®Google Scholar
• Parren PW, Ditzel H, Gulizia RJ, et al. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS. 1995;9(6):F1–F6.
   PubMed Web of Science ®Google Scholar
• Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol. 2001;75(17):8340–8347.
   PubMed Web of Science ®Google Scholar
• Stiegler G, Armbruster C, Vcelar B, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS. 2002;16(15):2019–2025.
   PubMed Web of Science ®Google Scholar
• Gardner MR, Kattenhorn LM, Kondur HR, et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature. 2015;519:87–91.
   PubMed Web of Science ®Google Scholar
• Butler D. Ebola raises profile of blood-based therapy. Nature. 2015;517:9–10.
   Web of Science ®Google Scholar
• Managed Care. Costs of biologics for inflammatory conditions vary. Available from: http://www.managedcaremag.com/archives/2014/9/costs-biologics-inflammatory-conditions-vary-0. Accessed October 31, 2015.
   Google Scholar
• The fix. Tobacco plants hold key to Ebola virus cure ZMapp. Available from: http://www.thefix.com/content/tobacco-plants-hold-key-ebola-cure. Accessed October 31, 2015.
   Google Scholar
• Schrand LM, Elliott JM, Ross MB, Bell EF, Mutnick AH. A cost-benefit analysis of RSV prophylaxis in high-risk infants. Ann Pharmacother. 2001;35(10):1186–1193.
   Web of Science ®Google Scholar
• Kamal-Bahl S, Doshi J, Campbell J. Economic analyses of respiratory syncytial virus immunoprophylaxis in high-risk infants: a systematic review. Arch Pediatr Adolesc Med. 2002;156(10):1034–1041.
   PubMedGoogle Scholar
• Glennie MJ, Johnson PW. Clinical trials of antibody therapy. Immunol Today. 2000;21(8):403–410.
   PubMedGoogle Scholar
• Dalle S, Thieblemont C, Thomas L, Dumontet C. Monoclonal antibodies in clinical oncology. Anticancer Agents Med Chem. 2008;8(5):523–532.
   Web of Science ®Google Scholar
• Schnepp BC, Johnson PR. Adeno-associated virus delivery of broadly neutralizing antibodies. Curr Opin HIV AIDS. 2014;9:250–256.
   Web of Science ®Google Scholar
• Haynes BF, Verkoczy L. AIDS/HIV. Host controls of HIV neutralizing antibodies. Science. 2014;344(6184):588–589.
   PubMed Web of Science ®Google Scholar
• Bommakanti G, Citron MP, Hepler RW, et al. Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci U S A. 2010;107:13701–13706.
   PubMed Web of Science ®Google Scholar
• Mallajosyula VV, Citron M, Ferrara F, et al. Influenza hemagglutinin stem-fragment immunogen elicits broadly neutralizing antibodies and confers heterologous protection. Proc Natl Acad Sci U S A. 2014;111:E2514–E2523.
   PubMed Web of Science ®Google Scholar
• Correia BE, Bates JT, Loomis RJ, et al. Proof of principle for epitope-focused vaccine design. Nature. 2014;507:201–206.
   PubMed Web of Science ®Google Scholar
• Li Y, O’Dell S, Walker LM, et al. Mechanism of neutralization by the broadly neutralizing HIV-1 monoclonal antibody VRC01. J Virol. 2011;85(17):8954–8967.
   Web of Science ®Google Scholar
• Blattner C, Lee JH, Sliepen K, et al. Structural delineation of a quaternary, cleavage-dependent epitope at the gp41-gp120 interface on intact HIV-1 Env trimers. Immunity. 2014;40(5):669–680.
   PubMed Web of Science ®Google Scholar
• Deng YQ, Dai JX, Ji GH, et al. A broadly flavivirus cross-neutralizing monoclonal antibody that recognizes a novel epitope within the fusion loop of E protein. PLoS One. 2011;6(1):e16059.
   Web of Science ®Google Scholar
• Lin HE, Tsai WY, Liu IJ, et al. Analysis of epitopes on dengue virus envelope protein recognized by monoclonal antibodies and polyclonal human sera by a high throughput assay. PLoS Negl Trop Dis. 2012;6(1):e1447.
   Web of Science ®Google Scholar
• Costin JM, Zaitseva E, Kahle KM, et al. Mechanistic study of broadly neutralizing human monoclonal antibodies against dengue virus that target the fusion loop. J Virol. 2013;87(1):52–66.
   PubMed Web of Science ®Google Scholar
• Owsianka A, Tarr AW, Juttla VS, et al. Monoclonal antibody AP33 defines a broadly neutralizing epitope on the hepatitis C virus E2 envelope glycoprotein. J Virol. 2005;79(17):11095–11104.
   PubMed Web of Science ®Google Scholar